283 related articles for article (PubMed ID: 17581233)
21. Staphylococcus aureus MurC participates in L-alanine recognition via histidine 343, a conserved motif in the shallow hydrophobic pocket.
Kurokawa K; Nishida S; Ishibashi M; Mizumura H; Ueno K; Yutsudo T; Maki H; Murakami K; Sekimizu K
J Biochem; 2008 Mar; 143(3):417-24. PubMed ID: 18084043
[TBL] [Abstract][Full Text] [Related]
22. Bacterial targets to antimicrobial leads and development candidates.
Rogers BL
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):211-22. PubMed ID: 15603255
[TBL] [Abstract][Full Text] [Related]
23. Exploiting genomics, genetics and chemistry to combat antibiotic resistance.
Hughes D
Nat Rev Genet; 2003 Jun; 4(6):432-41. PubMed ID: 12776213
[TBL] [Abstract][Full Text] [Related]
24. Drugs for bad bugs: confronting the challenges of antibacterial discovery.
Payne DJ; Gwynn MN; Holmes DJ; Pompliano DL
Nat Rev Drug Discov; 2007 Jan; 6(1):29-40. PubMed ID: 17159923
[TBL] [Abstract][Full Text] [Related]
25. A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling.
Székely R; Wáczek F; Szabadkai I; Németh G; Hegymegi-Barakonyi B; Eros D; Szokol B; Pató J; Hafenbradl D; Satchell J; Saint-Joanis B; Cole ST; Orfi L; Klebl BM; Kéri G
Immunol Lett; 2008 Mar; 116(2):225-31. PubMed ID: 18258308
[TBL] [Abstract][Full Text] [Related]
26. Correlation of carboxylic acid pKa to protein binding and antibacterial activity of a novel class of bacterial translation inhibitors.
Stiff CM; Zhong M; Sarver RW; Gao H; Ho AM; Sweeney MT; Zurenko GE; Romero DL
Bioorg Med Chem Lett; 2007 Oct; 17(19):5479-82. PubMed ID: 17709248
[TBL] [Abstract][Full Text] [Related]
27. A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds.
Donald RG; Skwish S; Forsyth RA; Anderson JW; Zhong T; Burns C; Lee S; Meng X; LoCastro L; Jarantow LW; Martin J; Lee SH; Taylor I; Robbins D; Malone C; Wang L; Zamudio CS; Youngman PJ; Phillips JW
Chem Biol; 2009 Aug; 16(8):826-36. PubMed ID: 19716473
[TBL] [Abstract][Full Text] [Related]
28. Promoting assembly and bundling of FtsZ as a strategy to inhibit bacterial cell division: a new approach for developing novel antibacterial drugs.
Beuria TK; Singh P; Surolia A; Panda D
Biochem J; 2009 Sep; 423(1):61-9. PubMed ID: 19583568
[TBL] [Abstract][Full Text] [Related]
29. Antibacterial drug discovery and structure-based design.
Barker JJ
Drug Discov Today; 2006 May; 11(9-10):391-404. PubMed ID: 16635801
[TBL] [Abstract][Full Text] [Related]
30. Discovery of lucensimycins A and B from Streptomyces lucensis MA7349 using an antisense strategy.
Singh SB; Zink DL; Huber J; Genilloud O; Salazar O; Diez MT; Basilio A; Vicente F; Byrne KM
Org Lett; 2006 Nov; 8(24):5449-52. PubMed ID: 17107044
[TBL] [Abstract][Full Text] [Related]
31. Antibacterial drug discovery--then, now and the genomics future.
Monaghan RL; Barrett JF
Biochem Pharmacol; 2006 Mar; 71(7):901-9. PubMed ID: 16494849
[TBL] [Abstract][Full Text] [Related]
32. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and antibacterial activity of 4''-O-heteroarylcarbamoyl derivatives of macrolide.
Xu P; Liu L; Jin ZP; Wang GQ; Liu J; Li Y; Lei PS
Bioorg Med Chem Lett; 2008 Oct; 18(20):5507-11. PubMed ID: 18815034
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, characterization and structure-activity relationship analysis of novel depsides as potential antibacterials.
Lv PC; Xiao ZP; Fang RQ; Li HQ; Zhu HL; Liu CH
Eur J Med Chem; 2009 Apr; 44(4):1779-87. PubMed ID: 18539361
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design.
Tsao DH; Sutherland AG; Jennings LD; Li Y; Rush TS; Alvarez JC; Ding W; Dushin EG; Dushin RG; Haney SA; Kenny CH; Malakian AK; Nilakantan R; Mosyak L
Bioorg Med Chem; 2006 Dec; 14(23):7953-61. PubMed ID: 16919463
[TBL] [Abstract][Full Text] [Related]
36. An aminoquinazoline inhibitor of the essential bacterial cell wall synthetic enzyme GlmU has a unique non-protein-kinase-like binding mode.
Larsen NA; Nash TJ; Morningstar M; Shapiro AB; Joubran C; Blackett CJ; Patten AD; Boriack-Sjodin PA; Doig P
Biochem J; 2012 Sep; 446(3):405-13. PubMed ID: 22721802
[TBL] [Abstract][Full Text] [Related]
37. Anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of MC21-B, an antibacterial compound produced by the marine bacterium Pseudoalteromonas phenolica O-BC30T.
Isnansetyo A; Kamei Y
Int J Antimicrob Agents; 2009 Aug; 34(2):131-5. PubMed ID: 19329285
[TBL] [Abstract][Full Text] [Related]
38. Small and lethal: searching for new antibacterial compounds with novel modes of action.
Pathania R; Brown ED
Biochem Cell Biol; 2008 Apr; 86(2):111-5. PubMed ID: 18443624
[TBL] [Abstract][Full Text] [Related]
39. Discovery of new Gram-negative antivirulence drugs: structure and properties of novel E. coli WaaC inhibitors.
Moreau F; Desroy N; Genevard JM; Vongsouthi V; Gerusz V; Le Fralliec G; Oliveira C; Floquet S; Denis A; Escaich S; Wolf K; Busemann M; Aschenbrenner A
Bioorg Med Chem Lett; 2008 Jul; 18(14):4022-6. PubMed ID: 18571407
[TBL] [Abstract][Full Text] [Related]
40. Using genomics to develop novel antibacterial therapeutics.
Nagaraj NS; Singh OV
Crit Rev Microbiol; 2010 Nov; 36(4):340-8. PubMed ID: 20670176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
